Alignment Healthcare Announces Pricing of Secondary Offering

Rhea-AI Summary

Alignment Healthcare (NASDAQ: ALHC) announced the pricing of a secondary offering of 13,167,733 common shares by an affiliate of General Atlantic at a public offering price of $19.46 per share. The Company will not receive proceeds from the sale.

The offering is expected to close on March 4, 2026, subject to customary closing conditions, with J.P. Morgan acting as underwriter. The offering is being made under a Form S-3 shelf registration that became effective on March 2, 2026.

Key Figures

Secondary shares offered: 13,167,733 shares Offering price: $19.46 per share Expected close date: March 4, 2026 +5 more

8 metrics

Secondary shares offered 13,167,733 shares Selling stockholder’s underwritten public offering

Offering price $19.46 per share Public offering price set by underwriter

Expected close date March 4, 2026 Scheduled closing of secondary offering

2025 revenue $3.95B Full-year 2025 revenue from recent 8-K

Revenue growth 46.1% YoY 2025 full-year revenue growth rate

2026 revenue guidance $5.14B–$5.19B Company’s 2026 revenue outlook

2025 adjusted EBITDA $109.9M Full-year 2025 adjusted EBITDA from 8-K

Health plan membership 236,300 members Q4 2025 ending membership

Market Reality Check

Price: $19.67 Vol: Volume 2,341,740 is sligh...

normal vol

$19.67 Last Close

Volume Volume 2,341,740 is slightly below the 20-day average of 2,444,561, suggesting no major pre-news volume spike. normal

Technical Price $19.67 is trading above the 200-day MA at $17.13, reflecting a prior uptrend into this offering.

Peers on Argus

Peers were mixed, with OSCR up 6.15%, CVS up 2.14%, PGNY and MOH modestly positi...

Peers were mixed, with OSCR up 6.15%, CVS up 2.14%, PGNY and MOH modestly positive, and CLOV down 0.49%. No momentum scanner signals or broad, synchronized sector move were flagged around this event.

Historical Context

5 past events · Latest: Feb 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 26	Earnings results	Positive	-5.9%	Beat 2025 guidance high end and raised 2026 revenue and EBITDA outlook.
Feb 23	Conference appearance	Neutral	-3.4%	Announcement of presentation at Leerink Partners Global Healthcare Conference.
Feb 05	Earnings date set	Neutral	-0.8%	Scheduled Q4 and full‑year 2025 earnings release and conference call.
Jan 21	Recognition/award	Positive	+2.5%	Named to 2026 Fortune World’s Most Admired Companies list in first eligible year.
Jan 20	Leadership/strategy	Positive	+1.1%	Appointed chief digital officer to accelerate AI-driven growth via AVA® platform.

Pattern Detected

Recent history shows occasional negative reactions to fundamentally positive updates, including strong earnings and conference news.

Recent Company History

Over the past few months, Alignment reported strong 2025 results with full‑year revenue of $3.95B and raised 2026 guidance, yet the stock fell 5.88% the next day. A conference appearance and an earnings-date announcement also saw mild declines. By contrast, reputational and strategic updates, such as the Fortune World’s Most Admired recognition and the appointment of a chief digital officer tied to the AVA® platform, drew modest positive reactions. Today’s secondary sale by a large holder follows this stretch of mixed trading responses to generally constructive company news.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-03-02

On Mar 2, 2026, Alignment filed an S-3ASR shelf registration that became effective immediately, allowing the company and named selling stockholders to offer a range of securities from time to time. Shelf usage is currently 0, so capacity under this registration remains fully unused based on available data.

Market Pulse Summary

This announcement details a 13,167,733-share secondary offering by an affiliate of General Atlantic ...

Analysis

This announcement details a 13,167,733-share secondary offering by an affiliate of General Atlantic at $19.46 per share, with Alignment receiving no proceeds. It follows strong 2025 results, including $3.95B in revenue and raised 2026 guidance to $5.14B–$5.19B. Investors may track how supply from selling shareholders interacts with prior insider sales and the new S-3ASR shelf, as well as upcoming execution against growth and profitability targets.

Key Terms

underwritten public offering, shelf registration statement, form s-3, prospectus supplement, +2 more

6 terms

underwritten public offering financial

"previously announced underwritten public offering of 13,167,733 shares"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

shelf registration statement regulatory

"pursuant to a shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"shelf registration statement on Form S-3, which has been filed"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"The offering will be made only by means of a prospectus supplement"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

prospectus regulatory

"by means of a prospectus supplement and an accompanying prospectus."

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

edgar regulatory

"by visiting EDGAR on the SEC website at www.sec.gov"

EDGAR is a system used by companies to share important financial and business information with the public. It functions like an online filing cabinet where investors can access official reports and documents that help them understand a company's financial health and operations. This transparency allows investors to make more informed decisions, much like checking a company's report card before investing.

AI-generated analysis. Not financial advice.

ORANGE, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) (“Alignment Healthcare” or the “Company”), an award-winning Medicare Advantage (MA) company, today announced the pricing of its previously announced underwritten public offering of 13,167,733 shares of its common stock by an affiliate of General Atlantic, L.P (the “Selling Stockholder”). The underwriter sold the shares at a public offering price of $19.46 per share. The Company will not receive any of the proceeds from the sale of the shares of its common stock being offered by the Selling Stockholder. The offering is expected to close on March 4, 2026, subject to customary closing conditions.

J.P. Morgan is acting as the underwriter for the offering.

The offering is being made pursuant to a shelf registration statement on Form S-3, which has been filed by the Company with the Securities and Exchange Commission (the "SEC") and became effective upon filing on March 2, 2026. The offering will be made only by means of a prospectus supplement and an accompanying prospectus. You may obtain these documents for free by visiting EDGAR on the SEC website at www.sec.gov, or by contacting: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Alignment Healthcare

Alignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ: ALHC), Alignment Health’s mission-focused team makes high-quality, low-cost care a reality for its Medicare Advantage members every day. Based in California, the company partners with nationally recognized and trusted local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology, AVA®. As it expands its offerings and grows its national footprint, Alignment upholds its core values of leading with a serving heart and putting the senior first.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include, among others, statements concerning the expected closing of the offering. Forward-looking statements are subject to risks and uncertainties and are based on assumptions that may prove to be inaccurate, which could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance. Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to attract new members and enter new markets, including the need for certain governmental approvals; our ability to maintain a high rating for our health plans on the Five Star Quality Rating System; our ability to develop and maintain satisfactory relationships with care providers that service our members; risks associated with being a government contractor; changes in laws and regulations applicable to our business model; risks related to our indebtedness; changes in market or industry conditions and receptivity to our technology and services; results of litigation or a security incident; and the impact of shortages of qualified personnel and related increases in our labor costs. There can be no assurance that Alignment Healthcare will be able to complete the offering on the anticipated terms, or at all. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our Annual Report on Form 10-K for the year ended December 31, 2025, and the other periodic reports we file with the SEC. All information provided in this release is as of the date hereof, and we undertake no duty to update or revise this information unless required by law.

Investor Contact
Harrison Zhuo
hzhuo@ahcusa.com

Media Contact
Priya Shah
mPR, Inc. for Alignment Healthcare
alignment@mpublicrelations.com

FAQ

What did Alignment Healthcare (ALHC) announce on March 3, 2026 about a secondary offering?

Alignment Healthcare priced a secondary offering of 13,167,733 shares at $19.46 per share. According to the company, the sale is by an affiliate of General Atlantic and the company will not receive any proceeds from the offering.

When is the ALHC secondary offering expected to close and who is the underwriter?

The offering is expected to close on March 4, 2026, subject to customary closing conditions. According to the company, J.P. Morgan is acting as the underwriter for the transaction and closing is conditional on customary requirements.

How many shares are being sold in the ALHC offering and at what price?

An affiliate of General Atlantic is selling 13,167,733 common shares at $19.46 per share. According to the company, the shares were priced in the underwritten public offering and are being sold by the selling stockholder.

Will Alignment Healthcare (ALHC) receive proceeds from the March 2026 secondary offering?

No, Alignment Healthcare will not receive any proceeds from the sale of the shares. According to the company, the common stock is being sold by the selling stockholder and proceeds will go to that affiliate, not the company.

Where can investors find the prospectus for the ALHC March 2026 offering?

Investors can obtain the prospectus supplement and accompanying prospectus for free from the SEC EDGAR website or by contacting J.P. Morgan's distribution addresses. According to the company, the offering is being made only by means of those prospectus documents.